Literature DB >> 8584586

Maintenance treatment of schizophrenia: a review of dose reduction and family treatment strategies.

N R Schooler1, S J Keith, J B Severe, S M Matthews.   

Abstract

Maintenance treatment in schizophrenia requires the integration of both medication and psychosocial treatment interventions for maximum effect. We review the recent evidence for strategies drawn from both domains. For the use of anti-psychotic medication we focus on studies of dose reduction using two strategies that differ in assumptions regarding the action of medication. They are: continuous low-dose and targeted, early intervention or intermittent treatment. For psychosocial interventions we focus on studies of family treatment. Regarding dose reduction, we conclude that both strategies are feasible but the targeted strategy incurs higher relapse and rehospitalization rates. Regarding family treatment, we conclude that family treatment provides benefits beyond other psychosocial interventions or usual care, but that there is no evidence for differences in efficacy among family treatments.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8584586     DOI: 10.1007/bf02238750

Source DB:  PubMed          Journal:  Psychiatr Q        ISSN: 0033-2720


  33 in total

Review 1.  Maintenance medication for schizophrenia: strategies for dose reduction.

Authors:  N R Schooler
Journal:  Schizophr Bull       Date:  1991       Impact factor: 9.306

2.  The community management of schizophrenia. A controlled trial of a behavioural intervention with families to reduce relapse.

Authors:  N Tarrier; C Barrowclough; C Vaughn; J S Bamrah; K Porceddu; S Watts; H Freeman
Journal:  Br J Psychiatry       Date:  1988-10       Impact factor: 9.319

3.  Influence of family life on the course of schizophrenic disorders: a replication.

Authors:  G W Brown; J L Birley; J K Wing
Journal:  Br J Psychiatry       Date:  1972-09       Impact factor: 9.319

4.  A controlled trial of social intervention in the families of schizophrenic patients: two year follow-up.

Authors:  J Leff; L Kuipers; R Berkowitz; D Sturgeon
Journal:  Br J Psychiatry       Date:  1985-06       Impact factor: 9.319

5.  High-dose versus low-dose strategies in the treatment of schizophrenia.

Authors:  J M Kane; A Rifkin; M Woerner; G Reardon; D Kreisman; R Blumenthal; M Borenstein
Journal:  Psychopharmacol Bull       Date:  1985

6.  A trial of family therapy v. a relatives group for schizophrenia.

Authors:  J Leff; R Berkowitz; N Shavit; A Strachan; I Glass; C Vaughn
Journal:  Br J Psychiatry       Date:  1989-01       Impact factor: 9.319

7.  Behavioural family management in schizophrenia. Outcome of a clinic-based intervention.

Authors:  E T Randolph; S Eth; S M Glynn; G G Paz; G B Leong; A L Shaner; A Strachan; W Van Vort; J I Escobar; R P Liberman
Journal:  Br J Psychiatry       Date:  1994-04       Impact factor: 9.319

Review 8.  Psychosocial treatment for schizophrenia.

Authors:  A S Bellack; K T Mueser
Journal:  Schizophr Bull       Date:  1993       Impact factor: 9.306

9.  A controlled trial of social intervention in the families of schizophrenic patients.

Authors:  J Leff; L Kuipers; R Berkowitz; R Eberlein-Vries; D Sturgeon
Journal:  Br J Psychiatry       Date:  1982-08       Impact factor: 9.319

10.  Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia. I. One-year effects of a controlled study on relapse and expressed emotion.

Authors:  G E Hogarty; C M Anderson; D J Reiss; S J Kornblith; D P Greenwald; C D Javna; M J Madonia
Journal:  Arch Gen Psychiatry       Date:  1986-07
View more
  2 in total

1.  Pancreatic necrosis: results of necrosectomy, packing, and ultimate closure over drains.

Authors:  G Branum; J Galloway; W Hirchowitz; M Fendley; J Hunter
Journal:  Ann Surg       Date:  1998-06       Impact factor: 12.969

2.  Functional recovery in patients with schizophrenia: recommendations from a panel of experts.

Authors:  Guillermo Lahera; José L Gálvez; Pedro Sánchez; Miguel Martínez-Roig; J V Pérez-Fuster; Paz García-Portilla; Berta Herrera; Miquel Roca
Journal:  BMC Psychiatry       Date:  2018-06-05       Impact factor: 3.630

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.